Given the very rare frequency of CSF1R TK pathogenic mutations detected in the screened patients (0.3% LOAD carriers), our hypotheses should foster genetic screening in larger cohorts of both early-onset AD and LOAD cases and functional studies. This evidence concerns the gene CSF1R and Alzheimer disease.